For what it is worth. The FDA didn’t have the top line data that Nader released the following day. Would their letter have changed? I would hope so. Saying no clinical benefit is pretty rough when we knew they were wrong on the CD-10 trial News 2 results. Now also the top line results. It would go along way towards a better atmosphere if they were to have a retraction about no benefit when clearly there is benefit. All though a small group of 62. The FDA standing tall and taking a hit would bolster the perception of everyone involved. The stock holders, the foreign countries we are involved with and just good principle in mending relations with CYDY. It would be a win win situation if they were to come clean.

Will this happen? Most likely not. I would be surprised that they would lower their pride enough to absorb some fault. They would think we would want more in the way of... just give us the EUA! So don’t expect a lowering of their pride and admission of any wrong doing so they don’t have to answer why they won’t give us a EUA without another trial. They will still want the trial. I know it hurts but life challenges are always testing us. We will get there and we won’t lose much in the USA because numbers are way down. Our focus will have to remain internationally. That’s where the revenue will be anyway. Quick trial results and we are on our way.

The most exciting thing this year to me is the LH’s trial and all the 60 bio markers we will track. This will allow us to know exactly how Leronlimab MOA works as a immune modulator not just as a CCR5 blocker that we know already. It will open up doors we might not of though of... well with the exception of Ohm. He thinks of them all. It will educate most of the rest of us.